NU51PS005178
Cooperative Agreement
Overview
Grant Description
Iowa Integrated Viral Hepatitis Surveillance and Prevention Programs - The IDPH Viral Hepatitis Program will utilize strategies, activities, and resources associated with this cooperative agreement to conduct viral hepatitis, implement prevention interventions, and to reduce the infectious disease consequences of drug use by improving access to services for people who inject drugs (PWID).
The Viral Hepatitis Surveillance and Prevention Program at the Iowa Department of Public Health (IDPH) intends to achieve several outcomes related to viral hepatitis over the five-year project period. Long-term outcomes include reduced viral hepatitis infections, increased access to care for people with viral hepatitis, improved health outcomes for people with viral hepatitis, reduced deaths among people with viral hepatitis, reduced health disparities, decreased overdose deaths, and decreased viral hepatitis infections associated with drug use.
The IDPH will collect, analyze, and monitor surveillance data related to Hepatitis A; acute and chronic Hepatitis B; and acute, chronic, and perinatal Hepatitis C. IDPH will also develop a plan to rapidly detect and respond to outbreaks of Hepatitis A, B, and C, and will establish a jurisdictional framework for the outbreak detection and response.
The IDPH will develop an elimination plan in year one that will serve as a blueprint to achieve long-term outcomes and will outline evaluation methods. Additionally, the development of a Viral Hepatitis Advisory Council (TAC) will increase stakeholder engagement and provide guidance to the Viral Hepatitis Program.
The IDPH will increase testing and referral to care. Routine HCV and HBV testing will increase in labs and health systems. Testing will also increase among people who inject drugs (PWID) in high impact settings. The IDPH will also increase provider capacity to treat HCV and HBV and will build systemic intervention to increase the number of people referred and linked to medical care.
Through Component 3, the IDPH will increase access for people who inject drugs (PWID) to evidence-based prevention interventions and the "PWID Service-Bundle"; reduce viral hepatitis, HIV, and other infections; reduce drug-related overdoses; and improve health outcomes for PWID.
The Viral Hepatitis Surveillance and Prevention Program at the Iowa Department of Public Health (IDPH) intends to achieve several outcomes related to viral hepatitis over the five-year project period. Long-term outcomes include reduced viral hepatitis infections, increased access to care for people with viral hepatitis, improved health outcomes for people with viral hepatitis, reduced deaths among people with viral hepatitis, reduced health disparities, decreased overdose deaths, and decreased viral hepatitis infections associated with drug use.
The IDPH will collect, analyze, and monitor surveillance data related to Hepatitis A; acute and chronic Hepatitis B; and acute, chronic, and perinatal Hepatitis C. IDPH will also develop a plan to rapidly detect and respond to outbreaks of Hepatitis A, B, and C, and will establish a jurisdictional framework for the outbreak detection and response.
The IDPH will develop an elimination plan in year one that will serve as a blueprint to achieve long-term outcomes and will outline evaluation methods. Additionally, the development of a Viral Hepatitis Advisory Council (TAC) will increase stakeholder engagement and provide guidance to the Viral Hepatitis Program.
The IDPH will increase testing and referral to care. Routine HCV and HBV testing will increase in labs and health systems. Testing will also increase among people who inject drugs (PWID) in high impact settings. The IDPH will also increase provider capacity to treat HCV and HBV and will build systemic intervention to increase the number of people referred and linked to medical care.
Through Component 3, the IDPH will increase access for people who inject drugs (PWID) to evidence-based prevention interventions and the "PWID Service-Bundle"; reduce viral hepatitis, HIV, and other infections; reduce drug-related overdoses; and improve health outcomes for PWID.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Iowa
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 83930% from $3,395 to $2,852,829.
Iowa Department Of Public Health was awarded
Cooperative Agreement NU51PS005178
worth $2,852,829
from National Center for HIV, Viral Hepatitis, STD, and TB Prevention in May 2021 with work to be completed primarily in Iowa United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.283 Centers for Disease Control and Prevention Investigations and Technical Assistance.
The Cooperative Agreement was awarded through grant opportunity Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments.
Status
(Ongoing)
Last Modified 8/6/25
Period of Performance
5/1/21
Start Date
4/30/26
End Date
Funding Split
$2.9M
Federal Obligation
$0.0
Non-Federal Obligation
$2.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for NU51PS005178
Transaction History
Modifications to NU51PS005178
Additional Detail
Award ID FAIN
NU51PS005178
SAI Number
NU51PS005178-810346570
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
State Government
Awarding Office
75CDC1 CDC Office of Financial Resources
Funding Office
75CVJ0 CDC NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TUBERCULOSIS PREVENTION
Awardee UEI
S47QLSY37VS1
Awardee CAGE
1XUE7
Performance District
IA-90
Senators
Charles Grassley
Joni Ernst
Joni Ernst
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Health and Human Services (075-0950) | Health care services | Grants, subsidies, and contributions (41.0) | $1,178,268 | 99% |
Modified: 8/6/25